Hoth Therapeutics, Inc HOTH 深 滬
等待開盤 07-25 09:30:00 美东时间
1.30
-0.060
-4.41%
華盛通- 最 高1.38
- 今 開1.37
- 成交量 18.91万股
- 最 低 1.29
- 昨 收 1.36
- 總市值 1717.16万
- 52周最高 3.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.58
- 委 比 52.33%
- 總股本 1320.89万
- 歷史最高 347.00
- 量 比 0.38
- 振 幅 6.62%
- 歷史最低 0.58
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hoth Therapeutics Announces CRADA With U.S. Department Of Veterans Affairs And FAVER To Evaluate GDNF As Metabolic Therapy Targeting Obesity And Hepatic Steatosis
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for
07-22 20:20
Hawthorn Bancshares joins Russell 3000® and Russell 2000® Indexes in FTSE Russell’s 2025 Reconstitution
Hawthorn Bancshares, Inc. (NASDAQ: HWBK) has been included in the Russell 3000 and Russell 2000 indexes, effective today. The Russell 3000 includes the largest 3,000 U.S. companies by market cap, while the Russell 2000 focuses on small-cap firms. CEO Brent M. Giles stated the inclusion reflects the company's growth and progress, enhancing visibility in the investment community.
06-30 20:48
Hoth Therapeutics Advances HT-001 for Cancer Treatment
Hoth Therapeutics ( ($HOTH) ) has provided an announcement. Hoth Therapeutics h...
06-25 04:36
Hoth Therapeutics' HT-001 Achieves 100% Response In Phase 2a Trial For EGFR Inhibitor-Related Skin Toxicities
Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.Hoth Therapeutics will host a Key Opinion Leader (KOL)
06-24 22:37
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
Developed to address EGFR inhibitor-induced skin toxicities in cancer patients NEW YORK, June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceut...
06-23 20:03
Hoth Therapeutics to Attend 2025 BIO International Convention
NEW YORK, June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients...
06-16 20:00
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.
06-12 20:52
Hoth Therapeutics Announces Key Opinion Leader Event Showcasing HT-001, Topical Therapeutic, Designed To Treat Debilitating Skin Toxicities Caused By EGFR Inhibitor Cancer Therapies
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive CareCase Study and Interim Clinical Trial Results Will Be DiscussedNEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.
06-05 20:16
Hoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'
HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity.IND filing
05-12 19:32
